Moneycontrol News
Shares of Granules India gained 2 percent in the early trade on Tuesday as company received USFDA nod for Methocarbamol tablets.
The US Food & Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) filed by company for Methocarbamol tablet 500 mg and 750 mg.
The approved ANDA is the bioequivalent and therapeutically equivalent to reference listed drug (RLD) of Robaxin 500 mg and 750 mg of Auxilium Pharmaceuticals, LLC.
The company intends to commercialise this product shortly.
At 09:30 hrs Granules India was quoting at Rs 101.35, up Re 1, or 1 percent on the BSE.
Posted by Rakesh Patil
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
